M
Maria G. Belvisi
Researcher at National Institutes of Health
Publications - 275
Citations - 17371
Maria G. Belvisi is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Sensory nerve & Cholinergic. The author has an hindex of 73, co-authored 269 publications receiving 16021 citations. Previous affiliations of Maria G. Belvisi include Aventis Pharma & AstraZeneca.
Papers
More filters
Journal ArticleDOI
Cough and airway disease: The role of ion channels.
Sara J. Bonvini,Maria G. Belvisi +1 more
TL;DR: It is concluded that these ion channels, given their expression profile and their role in the activation of sensory afferents and the cough reflex, may represent excellent therapeutic targets for the treatment of respiratory symptoms in chronic lung disease.
Journal ArticleDOI
Novel role for the liver X nuclear receptor in the suppression of lung inflammatory responses.
Mark A. Birrell,Matthew C. Catley,Elizabeth Hardaker,Sissie Wong,Timothy M. Willson,Kerryn McCluskie,Thomas Leonard,Stuart N. Farrow,Jon L. Collins,Saleem Haj-Yahia,Maria G. Belvisi +10 more
TL;DR: This study is the first to demonstrate anti-inflammatory actions of LXRs in the lung, and suggests that LXR ligands have utility in the treatment of lung diseases that involves chronic inflammation mediated by macrophages and neutrophils.
Journal ArticleDOI
Role of transient receptor potential and pannexin channels in cigarette smoke-triggered ATP release in the lung
Matthew Baxter,Suffwan Eltom,Bilel Dekkak,Liang Yew-Booth,Eric Dubuis,Sarah A. Maher,Maria G. Belvisi,Mark A. Birrell +7 more
TL;DR: Extracellular ATP is increased in the COPD affected lung and may play a key role in driving disease pathophysiology and a novel mechanism which may be responsible for CS-induced ATP release is uncovered.
Journal ArticleDOI
Peroxisome proliferator-activated receptors as novel targets in lung disease.
Maria G. Belvisi,David J Hele +1 more
TL;DR: PPARs are novel targets for lung disease, and the continued work with PPAR agonists may result in a potential new treatment for these chronic inflammatory lung diseases.
Journal ArticleDOI
Soft steroids: a new approach to the treatment of inflammatory airways diseases.
Maria G. Belvisi,David J Hele +1 more
TL;DR: Ciclesonide, a pro-drug soft steroid, has demonstrated efficacy without side effects in a once daily formulation in asthma patients and is being developed for the treatment of both asthma and chronic obstructive pulmonary disease with launches of aonce daily inhaler formulation expected in 2003.